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ABSTRACT 
Upregulation of type I Interferon (IFN-I)-induced genes is characteristic of both viral 
infections and Systemic lupus erythematosus (SLE). Here we show that mitochondrial 
antiviral signaling protein (MAVS), which normally forms a complex with retinoic acid 
gene I (RIG-I)-like helicases during viral infection, can be activated by oxidative stress 
alone, independent of RIG-I helicases. We observe that chemically generated oxidative 
stress induces MAVS oligomerization, which leads to mitochondrial hyperpolarization, 
decreased ATP production, and decreased spare respiratory capacity not observed 
otherwise in cells lacking MAVS. Peripheral blood lymphocytes of SLE patients, which 
also have increased oxidative stress, manifest spontaneous MAVS oligomerization that 
correlates with increased IFN-I. Consistent with this, inhibition of mitochondrial reactive 
oxygen species (ROS) by the mitochondria-targeted antioxidant MitoQ prevented 
oligomerization of MAVS and IFN-I production. Furthermore, ROS-mediated MAVS 
oligomerization and IFN-I production was reduced in cells expressing a MAVS-C79F 
variant that occurs in 30% of sub-Saharan Africans and has been linked with reduced 
secretion of IFN-I and milder SLE. These MAVS-C79F SLE patients also had reduced 
oligomerized MAVS. Collectively, our findings suggest that spontaneous MAVS 
oligomerization due to mitochondrial oxidative stress in SLE patients contributes to the IFN-
I signature characteristic of this syndrome. 
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INTRODUCTION  
Oxidative stress characterizes several infectious and autoimmune diseases, reflecting a 
disturbance in the normally tightly regulated balance between the production of various 
chemically reactive molecules, such as reactive oxygen species (ROS) and reactive 
nitrogen species (RNS), and antioxidants, including the glutathione and thioredoxin 
systems (1). During the early stages of certain RNA virus infections, retinoic acid gene I 
(RIG-I)-like helicases (RLHs) sense and bind to viral RNAs. RIG-I–RNA complexes 
associate with mitochondrial antiviral signaling protein (MAVS), which is located on the 
cytoplasmic face of the outer mitochondrial membrane (2). The interaction between RIG-I 
and MAVS is facilitated by mutual N-terminal caspase recruitment domains (CARD). RIG-I–
MAVS complex formation then leads to CARD-dependent MAVS oligomerization and the 
subsequent activation of IFN-I regulatory factors (IRFs) 3 and 7 and nuclear factor-κB (NF-
κB), which in turn induces the production of IFN-I and proinflammatory cytokines (3, 4). 
Recent findings suggest that the homeotypic CARD interaction of MAVS with the CARD 
of RIG-I can form protein aggregates and filaments on the surface of the mitochondria 
that can further activate MAVS proteins into functional clusters on the outer 
mitochondrial membrane (5). These high-molecular-weight MAVS complexes amplify 
the formation of the cytosolic signaling complex that activates IRFs and NF-κB (5, 6).  
Virus-induced MAVS aggregates are resistant to treatment with protease and detergent 
but are sensitive to reducing agents such as dithiothreitol (DTT) or ² -mercaptoethanol 
(² -Me) early in the induction process, suggesting that disulfide bond formation 
contributes to MAVS oligomer formation and stability (5). MAVS oligomerization may 
thus be a redox sensitive process. Reactive oxygen species (ROS) can modulate the 
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expression of a variety of inflammatory processes (7-9), and the recent finding that 
increased cellular ROS amplifies RIG-I signaling and MAVS function at the mitochondria 
supports this notion (5, 10). Accordingly, the RIG-I–MAVS signaling pathway is also 
enhanced by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2), 
a cytoplasmic source of ROS (11). Conversely, repression of mitochondrial ROS 
(mROS) production by cytochrome C oxidase complex subunit 5 (COX5B) inhibits 
MAVS aggregation and downstream signaling (12). Although recent work by Xu, et al. 
(6) defined the structural basis of the MAVS–CARD self-interaction, it is currently 
unknown as to how MAVS oligomerization might occur in response to oxidative stress in 
the absence of viral infection (6).  
A recent study by one of our groups showed that peripheral blood lymphocytes (PBL), 
particularly T cells, from patients with systemic lupus erythematosus (SLE) show an 
increase in ROS with corresponding mitochondrial hyperpolarization and increased 
mitochondrial electron transport chain activity at complex I (13). In turn, enhanced 
mROS production leads to oxidative modifications of many cellular proteins, lipids, and 
DNA (14, 15). Moreover, the depletion of cytosolic ATP associated with mitochondrial 
hyperpolarization predisposes T lymphocytes to death by necrosis in SLE (16-22). 
Increased amounts of serum IFN-I in SLE patients were first reported over 20 years ago 
(23), but only recently has the role of IFN-I in the pathogenesis of SLE been fully 
appreciated (24). More than half of SLE patients display excess production of IFN-I and 
upregulation of a group of IFN-I–stimulated genes that are associated with active 
disease (25, 26). Several recent observations have linked SLE risk alleles to both the 
production of, and response to, IFN-I (27). Noteworthy among these is a single nucleotide 
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polymorphism (SNP) in the CARD domain of MAVS that changes a cysteine to 
phenylalanine at position 79 (C79F) (28). MAVS-C79F occurs in 30% of the Sub-Saharan 
healthy population, and its presence in African-American SLE patients was associated with 
substantially reduced IFN-I, absence of autoantibodies against RNA-binding proteins, and 
overall milder SLE (28). This suggests that cysteine 79 could render MAVS susceptible to 
ROS-mediated modification through disulfide bridge formation among CARD domains, 
leading to MAVS oligomerization. Thus, those individuals bearing the MAVS-C79F 
variant might be somewhat protected from an overwhelming IFN-I inflammatory 
response to viral infections. Similarly, SLE patients with MAVS-C79F might also be 
protected from ROS-induced IFN-I production.  
Here we report that MAVS oligomerization during viral infection leads to decreased 
oxygen consumption, reduced mitochondrial biogenesis, and a higher mitochondrial 
membrane potential, resembling the mitochondrial phenotype observed in T cells of 
SLE patients. We further show that chemically induces oxidative stress is sufficient to 
induce MAVS oligomerization, leading to significant IFN-I production. Furthermore, 
spontaneous MAVS oligomerization is observed in PBL and plasma of several SLE 
patients, but rarely in age- and sex-matched healthy controls. Additionally we show that 
patients with oligomerized MAVS have decreased capacity for oxidative phosphorylation 
and increased plasma IFN-I. MAVS oligomerization can also be inhibited by the 
mitochondria-targeted antioxidant MitoQ. Additional analysis revealed that ROS-induced 
oligomerization of MAVS and consequent IFN-I production are greatly reduced in cell lines 
expressing the MAVS-C79F variant but not significantly during viral infection. Consistent 
with this, SLE patients bearing the MAVS-C79F variant had reduced MAVS 
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oligomerization. Together these findings suggest a mechanism by which mitochondrial 
dysfunction and oxidative stress can result in the IFN-I signature of SLE patients via MAVS 
oligomerization. 
RESULTS 
MAVS oligomerization decreases ATP production and mitochondrial spare 
respiratory capacity. ROS and redox-regulating proteins such as COX5B or NOX2 
that can modify mitochondrial and cytoplasmic ROS quantity, respectively, can regulate 
the MAVS-mediated antiviral pathway through altering the expression of MAVS itself 
(12). However, the role of MAVS depletion or cleavage in cellular mitochondrial 
oxidative metabolism has not been investigated. Thus, we examined mitochondrial 
function and metabolism in wild-type (WT) or MAVS-deficient (MAVS-KO) mouse 
embryonic fibroblasts (MEFs) during infection with either Coxsackievirus B3 (CVB3), 
Sindbis virus (SINV), or after transfection with an RNA containing a triphosphate 
incorporated at the 5′ end (5′-ppp) that is a specific ligand for RIG-I. Both CVB3 and 
SINV are single-stranded, positive-sense RNA viruses with the ability to activate the 
RIG-I pathway (29). However, unlike SINV, CVB3 has the additional ability to cleave 
MAVS at Gln148 with its 3Cpro protease (30). During the initial 12 h following CVB3 and 
SINV infection, or 5’-ppp RNA transfection, we observed that both ROS and 
mitochondrial membrane potential (∆Ψm) increased (Fig. 1, A and B), in agreement with 
previous findings (31, 32). However, beyond the 12 h time point, in contrast to SINV and 
5’-ppp-RNA, CVB3-induced cleavage of MAVS paralleled a marked reduction in cellular 
ROS and ∆Ψm (Fig. 1, A to C). Changes in ∆Ψm and ROS during viral infection or 5′-
ppp–RNA stimulation also correlated positively with MAVS oligomerization (Fig. 1D). 
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Particularly striking was that no increase in ROS or ∆Ψm was observed during viral 
infection of MAVS-KO cells (Fig. 1, A and B). This was also true of cells expressing a 
truncated form of MAVS cleaved at Gln148, which lacks the CARD domain required for 
MAVS oligomerization (Fig. S1). Using the mitochondria-targeted, redox-sensitive di-
cysteine green fluorescent protein (roGFP) as a probe (33), we determined that the 
increased matrix thiol oxidation during viral infection or stimulation with 5′-ppp–RNA 
originated primarily in mitochondria (Fig. 1E).  
We observed elongation and further swelling of mitochondria following viral infection 
and 5’-ppp-RNA exposure (Fig. S1), consistent with previous observations (34-36). 
Mitochondrial morphological alterations that occur along with changes in mitochondrial 
membrane polarization can also lead to changes in respiration, and ATP production 
(37). To establish whether MAVS influences cellular metabolism during an innate 
immune response to viral infection, we measured total ATP production (Fig. 1F) and the 
ATP/ADP ratio (Fig. 1G) in MAVS-WT and MAVS-KO cells before and following 
infection with CVB3, or transfection with 5′-ppp–RNA. Interestingly, we observed that 
prior to infection MAVS-KO cells manifested a nearly 3-fold higher amount of cellular 
ATP than MAVS-WT cells (Fig. 1F). This high quantity of ATP in MAVS-KO cells 
correlated with a higher ATP/ADP ratio (Fig. 1G). Following CVB3 infection, the total 
ATP and ATP/ADP ratio increased 2-fold in MAVS-WT cells but did not increase further 
in MAVS-KO cells (Fig. 1, F and G). Increase in ATP production or the ATP/ADP ratio 
following CVB3 infection in MAVS-WT cells approached the total steady state of ATP in 
MAVS-KO cells (Fig. 1, F and G), and corresponded closely with the cleavage pattern of 
MAVS during CVB3 infection (Fig. 1C) is suggestive of a causative relationship. 
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Interestingly, we did not observe the same increase in ATP/ADP in cells transfected 
with 5′-ppp–RNA, which can continually activate RIG-I and MAVS oligomerization. In 
this case, following a small spike, the amount of ATP declined over time (Fig. 1F), 
suggesting that RIG-I and MAVS activation lowered the total quantity of ATP in the 
cells.  
To further assess the bioenergetic profile during viral infection in the presence or 
absence of MAVS, we initially examined the oxygen consumption rate (OCR) as an 
indicator of oxidative phosphorylation using a Seahorse extracellular flux analyzer (38). 
To assess mitochondrial respiratory capacity we sequentially treated cells with 
oligomycin (to block ATP synthesis), the ionophore FCCP (to uncouple mitochondria 
and thereby maximally stimulate the electron transport chain (ETC)), and rotenone (to 
block ETC complex I) (Fig. 1H). We observed that CVB3-infection and 5′-ppp–RNA-
treatment of MAVS-WT cells manifested significantly lower basal OCR than mock-
treated cells, and a very minimal response to FCCP treatment, suggesting impaired 
spare respiratory capacity (SRC) (Fig. 1, I and J). Three hours post-infection, at a time 
when the CVB3 3Cpro protease had produced only a small amount of cleaved MAVS 
(Fig. 1C), the metabolic profile of CVB3-infected cells did not differ from cells 
transfected with 5’-ppp-RNA (Fig. 1I). However, the same metabolic profile measured at 
24 h when CVB3 3Cpro had significantly cleaved MAVS, showed that CVB3-infected 
cells, but not 5′-ppp–RNA transfected cells, returned to basal capacity of OCR and SRC 
(Fig. 1J). Under the same conditions, MAVS-KO cells showed higher baseline OCR and 
SRC than MAVS-WT cells but, unlike MAVS-WT cells, this state did not significantly 
change with CVB3 infection or 5′-ppp–RNA treatment. (Fig. 1, K and L). The findings 
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from three separate OCR studies in MAVS-WT vs MAVS-KO MEFs is summarized in 
Figure 1, M and N. As prolonged cell culture can impact the phenotype of MEF, we 
tested whether metabolic differences are indeed due to the differences in genotype 
using primary splenocytes from MAVS-WT vs MAVS-KO mice and observed the same 
phenotype as in MEFs (Fig. 1, O and P). In contrast to the differences in oxygen 
consumption, the basal extracellular acidification rate (ECAR), a readout of lactate 
production by glycolysis, was very similar between MAVS-WT and MAVS-KO MEFs 
(Fig. S1). Collectively, these findings suggest that MAVS oligomerization inhibits 
mitochondrial respiration and ROS production.  
 
Oxidative stress independent of viral infection induces MAVS oligomerization. To 
further evaluate the influence of oxidative stress on MAVS oligomerization in the 
presence or absence of viral infection, we used two gel systems. First, we adapted a 
Tris-Glycine-eXtended (TGX) gradient polyacrylamide gel system to detect with high 
resolution MAVS aggregates (39). Second, to better detect the total amount of MAVS 
oligomers, we used Tris-Glycine agarose gels, which allow improved migration of large 
molecular weight complexes (5). We assessed MAVS oligomerization during chemically 
induced oxidative stress using glucose oxidase (GOx), which generates H2O2 in the 
process of catalyzing the oxidation of glucose to D-glucono-´ -lactone, and compared it 
with SINV infection (40). At concentrations of 10–20 µg/mL, GOx increases cytoplasmic 
ROS at a quantity close to those observed during viral infection (41). We observed that 
GOx-mediated oxidative stress alone was sufficient to induce MAVS oligomerization, in 
a manner similar to SINV infection (Fig. 2A). Of interest, GOx-induced MAVS 
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oligomerization was reversible when cell media were supplemented with β-
mercaptoethanol (β-Me) (Fig. 2A). This was much less apparent during SINV infection, 
where only a portion of the MAVS oligomers were reducible. This difference could 
reflect the fact that virus-induced oligomerization of MAVS involves both RIG-I-
CARD/MAVS-CARD dimerization as well as ROS-induced MAVS oligomerization, 
whereas GOx involves only the latter process. To address the possibility that the 
observed MAVS oligomerization might be an artifact of cysteine dimerization induced 
during cell lysis and processing for electrophoresis, freshly prepared cells were 
homogenized in buffer containing iodoacetamide, which covalently binds to free thiol 
groups of cysteines to prevent further disulfide bond formation. The presence of 100 µM 
iodoacetamide did not result in a decrease in MAVS oligomers either following GOx 
treatment or SINV infection (Fig. S2A). MAVS oligomerization induced by GOx also led 
to the formation of the MAVS signaling complex as detected by co-precipitation of 
MAVS via its N-terminal His-tag. Within 3 h post ROS induction, we observed the 
association of TRAF2, TANK, TRADD, and RIPK1 with MAVS, suggesting that both 
interferon regulatory factors and the NF-κB branch of the MAVS signaling complex had 
occurred (Fig. 2B).  
MAVS oligomerization induced by GOx correlated with increased ∆Ψm (Fig. 2C). In 
agreement with the ability of β-Me to reverse MAVS oligomerization, supplementation of 
media with β-Me also prevented mitochondrial hyperpolarization in cells treated with 
GOx, but not following SINV infection (Fig. 2C). MAVS oligomerization induced by GOx 
lead to increased secretion of IFN-β and IL-6, which was not observed in MAVS-
deficient cells, but treated with the compound (Fig. 2, D and E).  
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To determine whether ROS derived specifically from mitochondrial respiration could 
also induce MAVS oligomerization, we used the compound MitoParaquat (MitoPQ), a 
mitochondria-targeted superoxide generator that contains a paraquat moiety tethered to 
a positively charged lipophilic triphenylphosphonium (TTP) cation that drives MitoPQ 
accumulation within negatively charged mitochondria (42). Treatment of MEFs with 
moderate concentrations of MitoPQ (1 to 10 nM) led to an increased MAVS 
oligomerization (Fig. 2F), without causing significant cell death at the doses used (Fig. 
2G). Treatment of cells with MitoPQ also led to significant increase of IFN-β and IL-6 
secretion that was not observed in MAVS-KO cells treated with MitoPQ (Fig. 2, H and I). 
 
To further rule out a potential role of RIG-I-like receptors in the process of ROS-induced 
MAVS oligomerization, cells lacking either RIG-I or both RIG-I and MDA5 were treated 
with GOx, MitoPQ and specific ligands for RIG-I (5’-ppp-RNA) and MDA5 (poly(I:C)). As 
demonstrated by immunoblotting, GOx-induced MAVS oligomerization occurred in the 
absence of RIG-I or when both RIG-I and MDA5 were absent (Fig. 2J). MEFs lacking 
both RIG-I and MDA5, but not MAVS-deficient cells, showed elevation IFN-β (Fig. 2K) 
and IL-6 mRNA (Fig. S2B) following treatment with GOx and MitoPQ, which correlated 
with increased secretion of these cytokines (Fig. 2L and S2C). RIG-I, MDA5 or MAVS 
deficient cells treated with RIG-I or MDA5 ligands did not show an increase of IFN-β 
(Fig. 2, K and L) and IL-6 (Fig S2, B and C). To control whether RIG-I, MDA5 or MAVS 
deficient cells are capable to secrete pro-inflammatory cytokines, we have treated these 
cells with dsDNA, which leads to secretion of IFN-I and IL-6 in a RIG-I pathway 
independent manner (43). We have observed that dsDNA lead to equal IFN-β and IL-6 
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secretion in RIG-I, MDA5 or MAVS deficient cells, respectively (Fig. S2D). These 
findings support the view that ROS alone in the absence of viral infection is sufficient to 
induce MAVS oligomerization and downstream cytokine signaling independent of RIG-I 
and MDA5.  
 
Mitochondria-targeted antioxidant MitoQ reduces MAVS oligomerization and IFN-I 
secretion. MitoQ ([10-(4,5-Dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-
yl)decyl](triphenyl)phosphonium methanesulfonate) is a mitochondria-targeted 
antioxidant comprised of ubiquinol/ubiquinone bound to TTP (44). In mitochondria, 
MitoQ is continually recycled to the active ubiquinol antioxidant by complex II in the 
respiratory chain (44, 45). Cells pretreated with MitoQ prior to oxidative stress showed 
reduced MAVS oligomerization, which was more pronounced in cells treated with GOx 
than with SINV infection (Fig. 3A). MitoQ treatment led to at least an 80% decrease in 
MAVS oligomers in cells treated with GOx, whereas in cells infected with SINV MitoQ 
resulted in about a 40% decrease in MAVS oligomerization (Fig. 3B). As a control, cells 
pretreated with dTPP, which has the same mitochondria-targeting motif as MitoQ but 
lacks its antioxidant properties, did not demonstrate reversal of MAVS oligomerization 
due to SINV or ROS induction (Fig. 3A). Similar to the findings with β-Me treatment, the 
results with MitoQ again suggest that the nature or intensity of MAVS oligomerization 
induced by direct oxidative stress might differ from that stimulated by viral infection in 
which there is the additional heterodimerization of RIG-I-CARD with MAVS-CARD. 
Decreased MAVS oligomerization in the presence of MitoQ correlated with decreased 
mitochondrial hyperpolarization (Fig. 3C) and reduced IFN-I secretion (Fig. 3D).  
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MAVS oligomerizes in human PBMCs under oxidative stress and spontaneously 
in SLE patients. We extended the findings in MEFs to human PBMCs from healthy 
donors and observed that GOx induced pronounced MAVS oligomerization that 
appeared to be progressive, as we identified distinct MAVS bands of ~750 and >1200 
kDa (Fig. 4A). As observed in MEFs, MAVS oligomerization did not occur in PBMCs 
pretreated with MitoQ or grown in the presence of β-Me (Fig. 4A).  
We have previously observed that lymphocytes from SLE patients exhibit spontaneous 
increased ROS, hyperpolarization of mitochondria, and increased cell death (21). We 
thus tested whether MAVS is spontaneously oligomerized in PBMCs from SLE patients 
compared to age- and sex-matched healthy controls. Spontaneous MAVS 
oligomerization was assessed by agarose gel separation and was identified in the 
PBMCs of 14 of 17 SLE patients, whereas weak oligomerization was observed in 4 of 
the 17 healthy controls (Fig. 4, B and D). MAVS oligomers were also detected in the 
plasma of 12 of 17 SLE patients but not in healthy controls (Fig. 4, C and D). To exclude 
the possibility that the observed MAVS oligomerization spontaneously occurred during 
cell isolation from blood samples we added iodoacetamide, which did not decrease the 
detection of MAVS oligomers in cells or plasma (Fig. S3). Iodoacetamide reduced the 
total thiol concentration of both PBMCs and plasma homogenates by 80% and 94%, 
respectively (Fig. S3). These data demonstrate that MAVS oligomers are not artificially 
formed during tissue homogenization and processing, and further indicate that MAVS 
oligomers are stable in plasma. SLE plasma contained higher IFN-I than healthy 
controls (Fig. 4E) and the amount of IFN-I closely paralleled the degree of plasma 
14 
 
MAVS oligomerization (Fig. 4F). Metabolic analysis of PBMCs of SLE and healthy 
controls identified no difference in basal respiration (Fig. 4G), but showed statistically 
reduced maximal respiration, spare respiratory capacity, and the rate of ATP synthesis 
in the SLE patients (Fig. 4, H to J). These findings are similar to changes in respiratory 
capacity we observed during MAVS oligomerization induced by viral infection (Fig. 1, I 
to N).  
To further explore which subsets of cells within the PBMC population contributed to 
MAVS oligomerization in SLE patients, we fractionated PBMC into T cell, B cell, and 
monocyte pools, and analyzed each for the presence of MAVS aggregates. As shown in 
Figure 4K, for equivalent amounts of protein, T cells manifested the greatest amount of 
MAVS oligomers, followed by B cells with relatively little detected in monocytes. MAVS 
oligomers were not observed in the same cell subsets of healthy controls. These 
findings are consistent with our earlier findings showing that much of the increased ROS 
in SLE PBMC is in the T cell subset (20). Metabolic analysis of PBMC subsets showed 
that, in agreement with previously published work (46) that monocytes, unlike B and T 
cells, did not show strong oxidative phosphorylation (Fig. S4). Although basal, maximal 
and spare respiratory capacity were significantly reduced in both B cells and T cells of 
SLE patients, the reduction of these parameters in T cells was at least two -old greater 
(Fig. 4, L to N). Noteworthy, the rate of ATP synthesis was decreased only in T cells, 
not significantly in B cells, of SLE patients (Fig. 4N).  
 
MAVS oligomerization is reduced in the MAVS-C79F variant associated with 
milder SLE activity. SLE patients bearing a MAVS-C79F SNP have milder disease, 
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lower production of IFN-I, and lack autoantibodies to RNA-binding proteins (28). In 
addition, cells expressing MAVS-C79F secrete a lesser amount of inflammatory 
mediators such as IL-8, RANTES, and IFN-²  (28). Since this SNP modifies a cysteine 
residue, we considered that this might alter the ability of MAVS-C79F to form oligomers 
under oxidative stress. We thus initially reconstituted MAVS-KO MEFs with either 
human MAVS-WT, the C79F variant, or a combination of the two (Fig. 5A). We 
observed that cells reconstituted with the MAVS-C79F variant manifested lower 
amounts of MAVS oligomerization following treatment with GOx. The same C79F cells 
following SINV infection did not show significant decrease in high molecular weight 
MAVS oligomers as compared to GOx treatment but presence of moderate size 
oligomers was detected whose size might reflect trimer or tetramer formation (Fig. 5, A 
and B). Interestingly, although we have observed differences in the amount of MAVS 
oligomerization between SINV and GOx, IFN-I secretion was affected following both 
treatments (Fig. 5C). Further, under oxidative stress, cells expressing MAVS-C79F 
exhibited less mROS and ∆Ψm, suggesting that this variant had little capacity to promote 
mitochondrial hyperpolarization (Fig. 5, D and E).  
Based on these observations in MEFs, we examined MAVS oligomerization in 6 SLE 
MAVS-C79F patients, 4 SLE MAVS-WT patients, and 3 healthy controls, all from the 
original C79F SNP study (28), and whose plasma was frozen at the same time. We 
observed that MAVS oligomerization was significantly lower in the plasma of the MAVS-
C79F patients, compared to SLE patients bearing wild-type MAVS (Fig. 5, F and G). 
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MAVS oligomers from SLE patients can induce prion-like MAVS aggregates. 
MAVS has been reported to form oligomers in a prion-like manner (5, 6). We therefore 
examined whether MAVS oligomers detected in the plasma of SLE patients have the 
ability to induce MAVS oligomerization in purified mitochondria from wild-type MEFs that 
were not exposed to oxidative stress. We first purified the plasma MAVS oligomer 
fraction by immunoprecipitation using an anti-MAVS antibody cross-linked to protein G 
magnetic beads (Fig. 6, A and B). Plasma samples were initially pre-incubated with 
protein G magnetic beads alone to remove nonspecifically bound proteins, followed by 
incubation with anti-MAVS protein G beads. Following purification and elution, we 
observed that MAVS oligomers purified from different patients’ plasma had a fairly 
uniform molecular weight of ~1500 kDa (Fig. 6C). Purified MAVS-oligomers from 
patients or healthy age- and sex-matched healthy control plasma were incubated with 
freshly purified mitochondria from normal MEFs for 30 min in a respiration-promoting 
buffer. Unbound donor MAVS oligomers were then removed by re-purification of the 
mitochondria using anti-Tom22 magnetic beads, as illustrated in Figure 6A. As a 
positive control, we observed that GOx treatment of purified mitochondria induced 
MAVS oligomerization (Fig. 6C, lane 2), similar to treatment of intact cells (Fig. 2A). 
Significantly, we observed that MAVS oligomers isolated from SLE patient plasma 
induced MAVS oligomerization of isolated mitochondria (Fig. 6C, lane 3), and that this 
was significantly decreased in mitochondria pretreated with MitoQ (Fig. 6C, lane 4). 
Treatment of purified mitochondria with the plasma from a healthy control (C1) did not 
induce detectable high-molecular-weight MAVS oligomers (Fig. 6C, lane 5). As a 
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negative control, purified MAVS oligomers from SLE patient plasma did not associate 
with mitochondria isolated from MAVS-KO cells (Fig. 6C, lane 6).  
 
To further distinguish induced oligomers of endogenous MAVS from pre-existing SLE-
donor MAVS oligomers, we performed the same experiments with mitochondria from 
MAVS-KO MEFs that expressed His-tagged human MAVS-WT, MAVS-C79F, or a 
combination of the two. Following treatment with SLE MAVS-WT oligomers, we 
observed high-molecular-weight bands detected by the anti-His antibody, again 
demonstrating that donor SLE MAVS oligomers could induce aggregation of 
endogenous MAVS (Fig. 6D). Additionally, we observed reduced MAVS aggregation 
when mitochondria contained MAVS-C79F or a combination of MAVS-WT and MAVS-
C79F (Fig. 6D, lanes 3 and 4). Taken together, these data show that the MAVS 
oligomers in the plasma of SLE patients have the ability to induce prion-like 
oligomerization of endogenous MAVS.  
 
Dendritic cells take up prion-like MAVS aggregates. The ability of dendritic cells 
(DCs) to take up and propagate intact prions has been described (47-49). Observations 
in transmissible spongiform encephalopathies show that internalization of fluorescently 
labeled prions can be detected in DCs (50). However, experimental data defining the 
role that immune cells play in the possible uptake of exogenous MAVS prion-like 
aggregates and subsequent activation of inflammation has not been demonstrated. To 
examine whether human or murine DCs can internalize MAVS oligomers purified from 
plasma of SLE patients, we labeled MAVS with either Alexa Fluor 546 (Alx546) or Alexa 
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Fluor 488 (Alx488) (Fig. 7A). Prior to enriching and labeling MAVS oligomers from 
plasma, total plasma was first treated with protein G magnetic beads alone and filtered 
through 100-kDa cut-off membranes to remove non-specific small-molecular-weight 
oligomers and cytokines. We then bound MAVS oligomers from plasma with anti-
MAVS-protein G magnetic beads and coupled them to Alx546 or Alx488 while the 
MAVS oligomers were still bound to the MAVS antibody tethered to magnetic beads. 
This effectively removed excess dye without passing the material through another size-
exclusion resin. As a negative control, we also labeled plasma from healthy controls that 
was free of MAVS oligomers to exclude the labeling of other plasma proteins. TGX gel 
analysis confirmed that labeling did not affect the stability of MAVS oligomers in SLE 
plasma, nor did it induce it in healthy control plasma (Fig. 7A). As MAVS oligomerization 
was highest in patient samples P2-P4, we used these samples for further studies (Fig. 
7A). Quantification of MAVS aggregate fluorescence accounted for more than 85–90% 
of the total monomer MAVS obtained by treatment with ² -Me and detected by 
luminescence with a CARD domain-specific MAVS antibody.  
We then examined whether labeled MAVS aggregates could be taken up by DC derived 
from human peripheral blood monocytes (hDC) or murine bone marrow derived DC 
(BMDC) (51, 52). As a control, we also tested BMDC derived from MAVS-KO mice. We 
initially used confocal microscopy to verify the rate of MAVS internalization and to note 
its intracellular location relative to mitochondria using MitoTracker. Alx546-MAVS 
aggregate uptake and detection in both human hDCs and BMDCs occurred within 1 h 
(Fig. 7, B and C). We did not observe Alx546 cytoplasmic staining in DCs treated with 
Alx546-labeled plasma samples from healthy controls, as freely diffusing, non-
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associated MAVS yield significantly weaker fluorescence. (Fig. 7B). In contrast, 
exogenous MAVS oligomers required the presence of endogenous MAVS in order to 
associate with mitochondria, and to induce IFN-I production from host cells. The 
increase in intracellular MAVS-fluorescence stems from the localization and association 
of exogenous MAVS with mitochondria, which results in an increase of local 
fluorescence signal. Calculation of the colocalization correlation coefficient of Alx546-
MAVS and MitoTracker-green fluorescence demonstrated an association of exogenous 
MAVS and mitochondria, however this was substantially reduced in MAVS-KO BMDC 
(Fig. 7D). Mitochondrial colocalization of internalized MAVS aggregates also closely 
paralleled induced amounts of IFN-I secretion in wild-type BMDC, and was not detected 
in MAVS-KO BMDC. In addition, IFN-I was induced using MAVS aggregates from SLE 
patients (P2-P4), but not using healthy control plasma (C1, C2) (Fig. 7E).  
 
We further confirmed the association of internalized exogenous MAVS with 
mitochondria and endogenous MAVS by purifying mitochondria from BMDC. We 
observed that labeled MAVS oligomers from the plasma of the SLE patients, but not 
healthy control plasma, induced endogenous MAVS oligomerization (Fig. 7F, upper 
panel). We confirmed the presence of exogenous SLE MAVS aggregates in the 
mitochondrial fraction by direct detection of labeled Alx488-MAVS in the gel. In 
agreement with the experiments performed using isolated mitochondria, we could not 
observe MAVS oligomers in the mitochondrial fraction of BMDCs isolated from MAVS-
KO mice (Fig. 7F, lower panel). To control whether the fluorophore treatment alone of 
DCs could promote spontaneous MAVS oligomerization, we treated BMDCs with free 
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Alx488-fluorophore, which did not lead to increased MAVS expression or 
oligomerization (Fig. 7G). This demonstrated that any increased MAVS oligomerization 
following treatment with purified MAVs oligomers detected in samples P2-P4 originated 
from either the association of exogenous MAVS aggregate with endogenous MAVS on 
mitochondria or prion-like induced oligomerization.  
 
Finally, we observed that treatment of mitochondria isolated from BMDC with purified 
MAVS aggregates from SLE plasma (P1-P4), but not healthy controls (C1), resulted in 
increased mitochondrial colocalization of MAVS signaling complex proteins TRAF2, 
TANK, TRADD, and RIPK1, and the formation of active IRF3 dimers (Fig. 7H), 
consistent with the earlier findings for IFN-I secretion from BMDCs (Fig. 7E).  
 
DISCUSSION 
The current findings support a model in which oxidative stress alone can induce the 
oligomerization of MAVS, resulting in the activation of IFN-I and NF-κB pathways. The 
fact that spontaneous MAVS oligomerization is observed in the PBMCs of SLE patients 
provides an important mechanistic link between the observations of increased oxidative 
stress and mitochondrial dysfunction in SLE lymphocytes and the known IFN-I signature 
found in many SLE patients (53). This could suggest viral- and RNA-independent 
activation of MAVS and IFN-I in SLE. The findings also readily suggest that 
antioxidants, which can inhibit MAVS oligomerization, might be therapeutic in SLE. 
Such clinical trials have in fact been initiated (54). Finally, the inability of the MAVS-
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C79F variant to oligomerize under oxidative stress potentially explains why this variant 
is associated with milder forms of SLE (28).  
 
Mitochondria fulfill several key functions in cellular metabolic and antiviral signaling 
pathways, including their central role in ATP generation. Although it has been 
suggested that MAVS oligomerization during viral infection or increased MAVS 
expression can lead to mitochondrial dysfunction and cell death (55), its role in 
mitochondrial metabolism has not been previously addressed. We observed that MAVS 
was critical for the induction of ROS production during viral infection, as ROS was 
absent in MAVS-deficient cells. This suggests a possible feed-forward mechanism in 
which initial MAVS oligomerization by RIG-I binding to MAVS through mutual CARD 
domains drives ROS, which in turn results in further MAVS oligomerization. Indeed 
MAVS oligomerization can directly suppress the function of mitochondrial complexes I-
IV, in agreement with a recently identified interaction of COX5B with MAVS (12). Our 
findings that cells bearing oligomerized MAVS not only have a reduced rate of ATP 
synthesis, but also decreased mitochondrial spare respiratory capacity (SRC) is 
consistent with this model. SRC represents the extra available mitochondrial capacity a 
cell has to produce energy, and is thought to be critical for long-term cellular survival 
and function (56). In agreement with this model, CVB3-mediated cleavage of MAVS, or 
MitoQ treatment of cells with oligomerized MAVS, restores SRC.  
 
These findings suggest that MAVS cleavage and the resulting restoration of 
mitochondrial high basal and spare respiratory capacity could help CVB3 to persist by 
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preventing cell death through energetic exhaustion of the cell. Our data further support 
the above premise by showing that cells lacking MAVS have high basal OCR and SRC 
and therefore could be resistant to cell death. In agreement, previous studies indicate 
MAVS-deficient fibroblasts are resistant to Sendai virus-induced cell death (55).  
 
Our data show that both cellular and mitochondrial ROS can induce IFN-I and IL-6 
secretion, which is dependent upon the presence of MAVS. Interestingly, IFN-I and IL-6 
secretion is 3- to 4- fold higher in cells treated with MitoPQ than GOx, suggesting that 
superoxide produced in mitochondria is particularly potent in activating MAVS 
oligomerization. Another possible explanation is that GOx-induced ROS is more diffuse, 
and MAVS needs ROS to be localized in higher concentrations close to mitochondria in 
order to form disulfide bridges. Whether MAVS oligomerization is a secondary effect of 
mitochondrial dysfunction in SLE, or an initial driving force of mitochondrial dysfunction, 
is not known and will be further investigated. It will be of interest to determine whether 
treatment of SLE PBMC in culture with MitoQ, which is able to inhibit GOx-mediated 
MAVS oligomerization, will revive mitochondrial vitality. That MAVS oligomerization can 
be inhibited by antioxidants suggests its therapeutic potential for SLE. Such antioxidant 
trials in SLE are currently underway using N-acetylcysteine (54).  
 
In agreement with antioxidant data, suggesting a redox-mediated mechanism of MAVS 
oligomerization, our data show that MAVS-C79F is resistant to ROS-dependent 
oligomer formation. A potential explanation for how ROS induces MAVS oligomerization 
is through induction of cysteine disulfide bonding, which is being investigated. MAVS 
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has several cysteine residues, five of which reside within the CARD domain, including 
Cys79. This could explain why MAVS-C79F fails to oligomerize with ROS, or to induce 
IFN-I. There may be other cysteine sites that can also form disulfide bonds, and 
disruption of any one could also severely disrupt the ability of MAVS to aggregate in 
response to ROS. Additionally, we found that although the MAVS-C79F variant does not 
form higher-molecular-weight oligomers under oxidative stress, dimer-, tetramer-sized 
MAVS-C79F may still be present. Conceivably, the C79F variant may merely alter 
MAVS conformation such that it cannot form oligomers. In fact, the original study 
describing the MAVS-C79F SNP hypothesized that this variant may alter MAVS 
conformation resulting in a modified interaction with downstream signaling molecules 
such as TRAF3 (28). Additionally our data suggests that the C79F variant, found in 30% 
of healthy Sub-Saharan population, could be a natural adaptation and a protective 
measure against environmentally induced oxidative stress by UV exposure, without 
affecting antiviral MAVS function.  
 
In our model, ROS activates MAVS in an RIG-I helicases-independent fashion. 
However, recent data suggest that both MAVS and RIG-I helicases play prominent roles 
in SLE pathogenesis because an MDA5 gain-of-function mutant is associated with a 
higher IFN-I signature in several autoimmune diseases (24, 57, 58) and MAVS 
activation by endogenous retroviruses promotes T cell-independent B cell responses 
(59). It is feasible that ROS-production results in the formation of an endogenous RIG-I-
helicase-stimulatory RNA ligand that then acts via RIG-I or MDA5 to activate MAVS. We 
were able to show that MAVS oligomerization at the early stages of exposure to 
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oxidative stress is independent of such a scenario, as MAVS oligomerization occurred 
in ROS-exposed MEF that were RIG-I-deficient and MDA5 knocked-down. However, it 
is feasible that MAVS oligomerization could for example lead to a release of 
mitochondrial RNA, which is not capped at the 5’-ends, and could in a feedback loop 
stimulate RIG-I helicases.  
 
Cell type distribution can be altered in the PBMCs of SLE patients (60), and comparing 
MAVS oligomerization in whole PBMCs in patients and controls can be biased if there 
are cell-specific differences. Our data in agreement with previous studies suggests that 
T cells possessed the highest amount of spontaneously oligomerized MAVS in SLE 
patients. Another recent study has suggested that activation of the cGAS/STING 
pathway in neutrophils in SLE triggers IFN-I production and NETosis, a unique cell form 
of cell death (61). Dying cells are a likely source of plasma MAVS, given that SLE 
patients are known to have an increased proportion of dying cells in their PBMC. 
However, whether MAVS oligomerization occurs spontaneously in neutrophils needs to 
be determined. Our data suggest that MAVS is released into the plasma of SLE patients 
and then can be taken up by another cells, like for example DCs, where they act in prion 
like fashion to further amplify MAVS signaling and produce pro-inflammatory cytokines. 
It will be interesting to determine, how these prions can be eliminated by the cell and 
what is the stoichiometry and spatial organization of exogenous and endogenous MAVS 
complexes.  
 
25 
 
These collective findings suggest that MAVS oligomerization leads to a mitochondrial 
metabolic phenotype that could resemble the phenotype found in T lymphocytes of SLE 
patients, which manifest spontaneous mitochondrial hyperpolarization, increased ROS 
production, and diminished intracellular ATP (21). The increased and sustained IFN-I 
signature of SLE patients may be only one determinant of overall disease activity, 
however it is possible that MAVS oligomerization may contribute to the IFN-I signature 
in SLE. The detection of MAVS oligomers in SLE plasma suggests that this might be a 
useful diagnostic test for MAVS activation, which could identify subpopulations of SLE 
patients with IFN-I and dysfunctional mitochondria, which could be more responsive to 
antioxidant therapies. 
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Materials and Methods 
Cell culture, mice and human subjects. MAVS-deficient and matching WT MEFs, a 
kind gift of Z. J. Chen (2), were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Hyclone), supplemented with 10% heat-inactivated fetal calf serum (FCS) 
(Hyclone), 100 mM L-glutamine (Cellgro Mediatech), and 10,000 units/mL penicillin/10 
mg/mL streptomycin sulfate (Life Technologies). C57BL6 or B6;129-Mavstm1Zjc/J mice 
(The Jackson Laboratory) were maintained at the University of Vermont under a 
protocol approved by the Institutional Animal Care and Use Committee. Murine BMDCs 
were prepared as described by Inaba et al. (52). In brief, cells derived from femur bone 
marrow were cultured at a density of 5 × 105/mL in 10-cm plates in RPMI 1640 
(HyClone), supplemented with 5% heat-inactivated FCS, 100 mmol L-glutamine, 100 
mmol sodium pyruvate, 10,000 units/mL penicillin/10 mg/mL streptomycin sulfate, 5 × 
10−5 mol 2-mercaptoethanol (Sigma), and 10 µg/mL GM-CSF (Life Technologies). 
Human subjects were enrolled under a protocol approved by the University of Vermont 
Institutional Review Board. Samples from 17 SLE patients fulfilling the American 
College of Rheumatology diagnostic criteria were studied (62). 16 out of 17 patients 
were female, and the age of study participants was 47± 3. The disease activity was 
assessed by the SLE disease activity index (SLEDAI) scores, ranging from 0 to 10 (63). 
Upon informed consent, primary human PBMCs were obtained from heparinized whole-
blood samples from SLE patients. Control PBMCs were generated from age-, sex-, and 
ethnicity-matched healthy subjects. PBMCs were isolated using standard Ficoll gradient 
centrifugation as previously described (64). Cells were either used immediately to 
prepare lysates for immunoblotting or cultured at a density of 5 × 105/mL in a 12-well 
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culture plate with RPMI 1640 (HyClone), supplemented with 5% heat-inactivated FCS, 
100 mmol L-glutamine, 100 mmol sodium pyruvate, and 10,000 units/mL penicillin/10 
mg/mL streptomycin sulfate. Enriched monocytes from PBMCs were used to prepare 
hDCs using negative magnetic bead selection (Miltenyi), and were subsequently 
cultivated for 6 d in 10 µg/mL GM-CSF and 500 U/mL IL-4. All cells were maintained in 
a humidified chamber at 37°C and 5% CO2. 
 
Virus stocks. The CVB3 H3 strain was derived from an infectious cDNA clone as 
previously described (65). SINV strain S.A.A.R.86, a kind gift from R.•E. Johnston, was 
derived from a genomic cDNA clone (66). Viral titers were determined by plaque assay 
(67). Infected MEFs were prepared by inoculating cells with CVB3 or SINV in DMEM at 
a multiplicity of infection (MOI) of 1. Cells remained in contact with the virus for 45 
minutes to allow absorption, then washed with phosphate buffered saline, resuspended 
in fresh medium, and incubated for the indicated time periods before assays were 
performed. 
 
Reagents. Polyinosinic-polycytidylic acid (poly(I:C)) and 5′ triphosphate double-
stranded RNA (5′-ppp–dsRNA), both complexed with LyoVec, were purchased from 
InvivoGen. Mitochondria-targeted antioxidant MitoQ and the mitochondria-targeted 
superoxide generator MitoPQ, were generous gifts of M. Murphy (44). The control 
reagent TPP was purchased from Sigma. Reagents were added to cells at 
concentrations as indicated. GOx was purchased from Sigma and added to cultured 
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cells at a final concentration of 0.1 U/mL. Iodoacetamide was from Thermo Fisher, and 
used at a final concentration of 100 µM.  
 
Flow cytometry. ROS generation was measured using oxidized, green-fluorescent 
dihydrocalcein acetoxymethylester (DHC-AM) (Life Technologies) and flow cytometry. 
Single-cell suspensions of MEFs were prepared and ROS was assessed with 5 µM 
DHC-AM staining in culture medium for 30 minutes (68). 25 nM of cationic cell permeant 
dye tetramethylrhodamine ethylester (TMRE; Life Technologies) (69) were used to 
measure ∆Ψm. Additionally, MitoSox Red and MitoTracker Deep Red (Life 
Technologies) were used to measure mitochondrial ROS and mitochondrial mass, 
respectively. Flow cytometry was carried out on an LSRII (BD Biosciences), and FlowJo 
software (Tree Star) was used for analysis. 
 
Metabolism assay. Real-time analysis of OCR and ECAR was performed with an XF-
24 Extracellular Flux Analyzer (Seahorse Bioscience). Metabolic profiles were 
measured under basal conditions in non-buffered DMEM (Sigma) containing 25 mM 
glucose, 2 mM L glutamine, and 1 mM sodium pyruvate, in response to 1 µM 
oligomycin, 0.5 µM FCCP, and 1 µM rotenone/1 µM antimycin A (70). Total ATP was 
measured with the ATP Lite Kit (Perkin Elmer), and the ATP/ADP ratio was determined 
using the bioluminescence ADP/ATP Ratio Assay Kit from Sigma.  
 
Confocal microscopy imaging. WT and MAVS-deficient MEFs were transfected using 
Neon Transfection System with roGFP-Mito2 (Addgene plasmid #49437). Mito-roGFP is 
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a green fluorescent protein that targets the mitochondrial matrix and displays rapid 
changes in fluorescence in response to changes in ambient redox potential (33). After 
transfection, cells were seeded on poly-L-lysine-coated coverslips (Becton Dickinson) 
and cultivated in DMEM overnight to allow cell recovery and expression of roGFP, 
before infection with CVB3 or SINV. Mitochondrial localization and morphology were 
defined by staining cells with 100 nM Mitotracker Deep Red (Life Technologies) for 15 
min prior to fixation with 2% formaldehyde. Coverslips were embedded with Aqua-
Mount Slide Mounting Media (Polysciences) and analyzed with a Zeiss LSM 510 Meta 
confocal laser scanning microscopy system (63× N.A. = 1.4 objective). Images were 
processed with Volocity 3D Image Analysis Software (Perkin Elmer).  
 
IFN-I and proinflammatory cytokine measurement. ELISA was used to measure 
cytokine concentration in supernatant from cultured MEFs and BMDCs, and in sera of 
SLE patients and healthy control subjects. For assays, samples were centrifuged and 
IFN-²  and IL-6 were measured in triplicate using murine or human ELISA kits according 
to the manufacturer’s instructions (PBL Biosciences). The fold change in IFN-I or IL-6 
cells was calculated by directly comparing mock versus virus or chemical inducer of 
ROS. 
 
Quantitative real-time PCR for IFN-I and IL-6. Total RNA from MEF was isolated 
using the RNeasy kit (Qiagen) according to the manufacturer' instructions, and reverse 
transcribed using iScript Reserve Transcription Supermix (Biorad). Expression of IFN-β 
and IL-6 mRNA was detected with use of iQ SYBR Green Supermix (Biorad) with pre-
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validated primers as described previously (71). Data was analyzed using the 2” ” Ct 
method as described previously (72). 
 
Functional reconstitution of human MAVS in MAVS-deficient MEFs. To reconstitute 
His-tagged human WT or C79F MAVS, 3 µg vector pIRES carrying the respective 
sequences, were transfected into 1 × 106 MAVS-deficient MEFs using Neon 
Transfection System (Life Technologies). To select for stably transfected cells, 2.5 
µg/mL puromycin (Life Technologies) was added 24 h post-transfection for up to 5 days.  
 
MAVS and MDA5 knock-down in MEF using siRNA. Where indicated, siRNA was 
used to knock-down MAVS (TRC MAVS shRNA, Thermo Fisher) in MEF, or MDA5 in 
RIG-I-KO MEF (psiRNA-MDA5, InvivoGen). 3 µg plasmid was transfected into 1 × 106 
WT MEFs using Neon Transfection System (Life Technologies). To select for stably 
transfected cells, 2.5 µg/mL puromycin (Life Technologies) or zeocin (InvivoGen), 
respectively, was added 24 h post-transfection for up to 5 days. 
 
Anti-His-tag immunoprecipitation. MEF were disrupted in lysis buffer and anti-His-tag 
antibody (Life Technologies) was used to immunoprecipitate MAVS. Purification of 
precipitated MAVS was performed on a MagMAX Express Magnetic Particle Processor 
(Thermo Fisher), and MAVS and co-immunoprecipitated proteins were separated by gel 
electrophoresis and detected by immunoblotting as indicated below.  
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Denaturing gel electrophoresis. Cultured MEFs or human PBMCs were lysed in a 
sample buffer containing 2% SDS and insoluble cell fragments were removed by 
centrifugation. Plasma samples derived from SLE patients were collected and stored at 
−20°C until gel electrophoresis. BCA protein assay (Thermo Scientific) was used to 
determine protein concentrations in all samples were resolved with SDS-PAGE under 
denaturing conditions. Gels were transferred to PVDF membranes using a Trans-Blot 
Turbo Transfer System (BioRad).  
 
Semidenaturing detergent agarose gel electrophoresis (SDD-AGE). SDD-AGE was 
performed according to a published protocol with minor modifications (73). In brief, 
mitochondria were resuspended in sample buffer (0.5 × TBE, 10% glycerol, 2% SDS, 
and 0.0025% bromophenol blue) and loaded onto a vertical 1.5% agarose gel. After 
electrophoresis in the running buffer (1 × TBE and 0.1% SDS) for 35 min with a 
constant voltage of 75 V at 4°C, proteins were transferred to PVDF membranes using a 
Trans-Blot Turbo Transfer System (BioRad) for immunoblotting. 
 
Immunoblot analysis (Western Blotting). PVDF membranes were blocked in 5% 
solution of nonfat powdered milk in Tris-buffered saline. Antibodies used were specific 
for MAVS and Actin (Santa Cruz); RIPK1 and TRAF2 (BD Biosciences); TANK, TRADD, 
RIG-I, and GAPDH (Cell Signaling); MDA5 and COX4 (Abcam), Alexa 488 (Life 
Technologies), and IRF3 (Thermo Fisher), respectively. Immunoreactive proteins were 
visualized using HRP-labeled conjugates (Jackson Immuno Research) and developed 
using Clarity Western ECL substrate (Biorad). Chemiluminescence was detected and 
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recorded using a Biorad Chemidoc instrument. Densitometric measurements were 
performed in Image Lab image acquisition and analysis software (Biorad). 
 
Purification of MAVS-oligomers, mitochondrial isolation, and functional assay. 
MAVS antibody was covalently coupled to protein G magnetic beads (Life 
Technologies) using the bi-functional amine-reactive cross-linker disuccinimidyl 
suberate (DSS; Thermo Scientific). To avoid a sample contamination with proteins or 
protein complexes that nonspecifically bind to protein G, plasma samples were pre-
incubated with protein G magnetic beads without the cross-linked MAVS antibody. SLE 
patient plasma were incubated for 6 hours, after which the magnetic beads were loaded 
onto a column in a magnetic field and extensively washed. After the beads were eluted, 
MAVS-oligomers were released from MAVS-antibody by way of increasing ionic 
strength buffer, lower pH and gel filtration. Functionally intact mitochondria from cultured 
cells were isolated as described earlier (74). This method comprises a mechanical cell 
rupture, followed by a precipitation of mitochondria from cell lysates using magnetically 
labeled anti-TOM22 (Miltenyi Biotec) antibody. Mitochondria were inoculated with SLE 
patient or healthy control plasma in a respiration-promoting buffer containing 125 mM 
KCl, 5.0 mM KH2PO, pH 7.25, 15 mM ±-ketoglutarate and 2.0 mM ADP (75, 76). The 
reaction mixtures were centrifuged at 10,000 × g for 10 min, and the precipitates then 
analyzed using SDD-AGE. 
 
Functional assay of endogenous MAVS aggregation and activation in vitro.  
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Prior to enriching and labeling MAVS oligomers from the plasma, total plasma was 
treated with protein G magnetic beads alone and filtered with 100-kDa cut-off 
membranes to remove non-specific small-molecular-weight oligomers and cytokines. 
We then bound MAVS oligomers from plasma with anti-MAVS-protein G magnetic 
beads and coupled them to Alx546 or Alx488 while the MAVS oligomers were still 
bound to the MAVS antibody tethered to magnetic beads to remove excess dye without 
passing the material through another size-exclusion resin. Purified MAVS oligomers 
from SLE patient plasma were fluorescently labeled using either Alx488- or Alx546-
hydrazine (Life Technologies) Labeled MAVS oligomers were cocultivated with either 
BMDCs derived from WT or MAVS-deficient mice, or hDCs. Both murine BMDCs and 
human DCs were incubated for 1, 2, or 6 h. Confocal microscopy was used to analyze 
Alx546 fluorescence and its location. DCs were cultured on poly-L-lysine-coated 
coverslips and stained with MitoTracker Green (Life Technologies) and Hoechst 33342 
prior to fixation with 4% formaldehyde to define mitochondria and nuclei.  
 
Genotyping of SLE samples. Genomic DNA was extracted using Qiagen's DNeasy 
Blood and Tissue Kit per manufacture instructions. Unique genomic primers flanking 
MAVS Cys79 were designed using Primer-Blast (FP-CCCTGGGGGCCATATTAATCC/ 
RP- CATCAAATCGCCTCCGAGCA) and used both to PCR amplify and sequence 
exon2.  
 
Analysis of mitochondrial morphology by transmission electron microscopy. For 
ultrastructural analysis, cells were fixed for 1 h at 65 °C in 2% paraformaldehyde and 
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2.5% glutaraldehyde (Polysciences) in 100 mM sodium cacodylate buffer, pH 7.2. 
Samples were washed in cacodylate buffer and then post-fixed for 1 h in 1% osmium 
tetroxide (Polysciences). Samples were then extensively rinsed in distilled H2O before 
en bloc staining for 1 h with 1% aqueous uranyl acetate (Ted Pella). After several rinses 
in distilled H2O, samples were dehydrated in a graded series of ethanol and then 
embedded in Eponate 12 resin (Ted Pella). Sections (95 nm in thickness) were cut with 
an Ultracut UC7 ultramicrotome (Leica Microsystems), then stained with uranyl acetate 
and lead citrate, and viewed on a JEOL 1400 transmission electron microscope (JEOL 
USA) equipped with an AMT XR611 high resolution 11 megapixel mid-mount CCD 
camera (Advanced Microscopy Techniques). 
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FIGURES 
Figure 1. MAVS oligomerization induces ROS generation and regulates cellular 
metabolism. (A) Wild-type (WT, closed symbols) and MAVS-deficient (KO, open 
symbols) MEFs were infected with CVB3 or SINV (multiplicity of infection (MOI) = 1), or 
transfected with 1 µg 5’-ppp–RNA, and the total quantity of ROS was measured by 
FACS after 24 h using the oxidation-sensitive probe DHC (5 µM). (B) In parallel, the 
mitochondrial transmembrane potential (∆Ψm) was monitored using TMRE (25 nM). 
FACS data are mean (+/- SEM) of triplicate samples and are representative of three 
separate experiments. (C) The kinetics of MAVS cleavage in CVB3-infected MEFs was 
determined by immunoblotting. SINV-infected and MAVS-KO MEF served as controls. 
Data are representative of three independent experiments. (D) MAVS oligomerization in 
MEFs in response to CVB3 or SINV infection, or 5’-ppp-RNA transfection, was detected 
at the time points indicated using non-reducing gels and immunoblotting. Results were 
similar in three independent experiments. (E) To define the cellular source of ROS in 
CVB3-infected MEFs, Mito-roGFP-expressing MAVS-WT and MAVS-KO MEFs were 
analyzed 6 h following infection. MitoTracker Deep Red was used at 1 µM as a 
counterstain to define mitochondria. Confocal microscopic images are representative of 
three independent experiments. (F) Total ATP content of MAVS-WT and MAVS-KO 
MEFs after infection with CVB3 or transfection with 5’-ppp-RNA over a 24 h period was 
measured using a luminescence-based assay. ATP amounts across the 24 h period in 
mock infected WT or MAVS-KO cells are shown as controls. (G) Similarly, the ATP/ADP 
ratio in the same cells was measured 24 h after infection, or transfection, respectively. 
ATP and ATP/ADP ratios were determined in two independent experiments. (H) 
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Representative scheme, adapted from Seahorse Bioscience, of OCR measurement 
using a Seahorse XF24 Analyzer. Measurement of OCR in response to the injection of 
the ATP synthase inhibitor oligomycin, uncoupler FCCP, and complex I and III inhibitors 
rotenone and antimycin A, allowed for the calculation of the key metabolic parameters 
of basal mitochondrial respiration, maximal respiration, and spare respiratory capacity. 
(I-N) OCR measurements of MAVS-WT (I,J, closed symbols) and MAVS-KO (K,L, open 
symbols) MEFs as a function of CVB3 infection or 5’-ppp-RNA transfection. 
Measurements were made 3 h (I,K) or 24 h (J,L) post infection, or transfection. MAVS-
WT and MAVS-KO cells were measured simultaneously in the same assay plate, and 
data represent three experiments shown as mean ± SEM. (M,N) Measurements of 
basal respiration, maximal respiration, and spare respiratory capacity in MAVS-WT 
(closed bars) and MAVS-KO (open bars) MEFs. (O,P) OCR measurements from 
splenocytes of MAVS-WT (closed symbols) and MAVS-KO (open symbols) mice. 
Statistical analysis performed were two-way ANOVA. Statistical analyses performed 
were one-way ANOVA, followed by Sidak’s Multiple Comparison Test to examine pair-
wise differences, two-way ANOVA, or Repeated Measures ANOVA, followed by Tukey’s 
Multiple Comparisons Test to examine specific comparisons, as appropriate. (*p < 0.05, 
**p<0.005, ***p<0.0005, ****p<0.00005). 
 
Figure 2. Virus-independent, oxidative stress induces MAVS oligomerization and 
IFN-I secretion. (A) MAVS oligomerization in MAVS-WT or MAVS-KO MEFs after 
glucose oxidase (GOx) treatment (1 U/ml) or SINV infection for 6 h was detected using 
semi-denaturing agarose gel electrophoresis. Data are representative of three 
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experiments. (B) Immunoprecipitation of MAVS was used to detect its association with 
TRAF2, TANK, TRADD, and RIPK1 following GOx treatment. (C) ∆Ψm using TMRE in 
response to GOx treatment or SINV infection was measured in MAVS-WT (black bars) 
and MAVS-KO (white bars) MEFs. The ionophore FCCP (10 nM) served as a control in 
WT and MAVS-deficient cells (bars overlap). Data are representative of at least three 
experiments. (D) IFN-I and (E) IL-6 cytokine secretion in response to GOx treatment 
was determined by ELISA in supernatants of MAVS-WT (black bars) and MAVS-KO 
(white bars) MEFs. Data are presented as fold-changes rather than absolute 
concentrations to enable comparability. The fold change was calculated by comparison 
of mock and treated cells. At least three independent experiments are included in each 
graph. (F) The formation of MAVS-oligomerization in response to 10 nM of the 
mitochondrial ROS-inducer MitoPQ was determined by immunoblotting. (G) Cell death 
induction by increasing concentrations of MitoPQ was determined by FACS using live-
dead stain. (H) IFN-I (I) and IL-6 cytokine secretion by MAVS-WT (black bars) and 
MAVS-KO (white bars) MEFs induced by MitoPQ was measured by ELISA. Data are 
shown as mean ± SEM, and are representative of three experiments. (J) MAVS 
oligomerization in RIG-I-KO or RIG-I-KO/MDA5-knockdown (KD) MEFs was determined 
in the absence or presence of GOx. (K) Transcriptional activity and secretion of IFN-²  in 
WT (1), RIG-I-KO (2), RIG-I-KO/MDA5-KD (3) and MAVS-KO (4) MEFs in response to 
GOx, MitoPQ, poly(I:C) and 5’-ppp-RNA was measured by qPCR, and (L) IFN-²  
secretion was determined using ELISA. Statistical analyses performed were one-way 
ANOVA, followed by Sidak’s Multiple Comparison Test to examine pair-wise 
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differences, or Repeated Measures ANOVA, and followed by Tukey’s Multiple 
Comparisons Test to examine specific comparisons. (*p < 0.05, **p < 0.005) 
 
Figure 3. The mitochondria-targeted antioxidant MitoQ prevents MAVS-
oligomerization. (A) MAVS-WT MEFs were pre-treated with 100 µM MitoQ before 
treatment with GOx or SINV infection, and semi-denaturing gel electrophoresis was 
used to detect MAVS monomers and oligomers. dTTP (100 µM) which lacks the anti-
oxidant quinol residue served as a negative control. (B) The ratio of MAVS oligomers to 
monomers after GOx treatment or SINV infection, with or without MitoQ pre-treatment, 
was determined by densitometric measurement of immunoblots. (C) ∆Ψm in MEF after 
GOx+/-MitoQ and SINV+/-MitoQ treatment was measured by FACS using TMRE. (D) 
IFN-I secretion of MEF with or without MitoQ and GOx treatment or SINV infection was 
measured in cell culture supernatants using ELISA. Data shown are representative of 
three experiments, and bar graphs are mean ± SEM. Statistical analyses performed 
were two-way ANOVA (B, D), followed by Tukey’s Multiple Comparisons Test to 
examine specific comparisons or one-way ANOVA (C), followed by Sidak’s Multiple 
Comparison Test to examine pair-wise differences. (*p < 0.05, **p < 0.005). 
 
Figure 4. Virus-independent oxidative stress induces MAVS-oligomerization in 
human PBMC, and SLE patients manifest spontaneous MAVS oligomerization. (A) 
Freshly isolated human PBMCs were treated with GOx for the times indicated, and 
semi-denaturing agarose gel electrophoresis was used to detect MAVS oligomerization. 
Cells (MitoQ) or cell lysates (² -Me) were pretreated as indicated. Findings are 
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representative of three experiments. (B) Whole cell lysates and (C) plasma of SLE 
patients (n=8, P1 – P8) were detected by semi-denaturing agarose gel electrophoresis. 
Healthy, sex-, age-, and ethnicity-matched subjects served as controls (n=8, C1 – C8). 
(D) MAVS oligomerization in whole cell lysates (left panel) and plasma (right panel) of 
SLE patients (black circles) and healthy control subjects (white circles) was quantified 
by densitometric measurement of immunoblots. In WCL a ratio of MAVS monomer and 
oligomer was measured and in plasma MAVS oligomers were normalized to albumin. 
Each point represents MAVS oligomerization of one individual, which was determined in 
at least three independent experiments. (E) IFN-I secretion was measured by ELISA 
and compared to a commercially available standard plasma from healthy individual. (F) 
Comparison of plasma IFN-I and degree of MAVS oligomerization in SLE patients. (G-J) 
OCR determinations of basal respiration (G), maximal respiration (H), spare respiratory 
capacity (I), and ATP synthesis (J) from SLE patients (P) and healthy controls (C). (K) 
MAVS oligomer measurements in unfractionated whole PBMC (W), or B cell (B), T cell 
(T), and monocyte (M) fractions. Findings are representative of three patients and 
controls examined. (L-N) OCR measurements from whole PBMC (L), B cells (M), or T 
cells (N) of SLE patient (black bars) or healthy control (white bars). Findings are 
representative of three patients and three controls. Statistical analyses performed were 
Independent t-tests (D, E, G-J), two-way ANOVA (L-N) and Pearson’s Correlation 
Coefficient (F). (*p<0.05, **p<0.005, ***p<0.0005, ****p<0.00005).  
 
Figure 5. SLE MAVS-C79F SNP reduces MAVS oligomerization. (A) MAVS-WT 
MEFs, or MAVS-KO MEFs expressing either human MAVS-WT or the MAVS-C79F 
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SNP or combination of both, were infected with SINV, or exposed to GOx. MAVS 
aggregation was determined using 5% semi-denaturing TGX gels in sample buffer in 
presence or absence of 0.1% of ² -Me, allowing detection of oligomers and intermediate 
lower molecular weight MAVS oligomers following immunoblotting. Data represent one 
of at least three experiments. (B-E) Quantitation of MAVS oligomers (B), IFN-I 
production (C), ROS (D), and mitochondrial membrane potential (E) from the same 
samples as in (A). (F,G) Semi-denaturating, 1.5% agarose gel analysis (F) and 
densitometry (G) of MAVS oligomers from plasma of healthy controls, SLE MAVS-C79F 
and SLE MAVS-WT patients that were taken and frozen at the same time; the total of 
high weight oligomers (above 1000kDa) were analyzed in 4 independent experiments 
and normalized to the amount of detectable albumin in plasma. Statistical analyses 
performed were two-way ANOVA (C-E), including interaction terms, followed by Tukey’s 
Multiple Comparisons Test to examine specific comparisons or one-way ANOVA (G), 
followed by Sidak’s Multiple Comparison Test to examine pair-wise differences. 
(*p<0.05, **p<0.005). 
 
Figure 6. MAVS oligomers from SLE patients manifest prion-like activity. (A) 
Experimental design for the purification of MAVS oligomers from the plasma of SLE 
patients, and for the de novo reconstitution of SLE-MAVS oligomers with purified 
mitochondria from MAVS-WT MEFs, MAVS-KO MEFS, and MAVS-KO MEFs 
reconstituted with WT and/or C79F MAVS. MAVS antibody was covalently linked by 
Disuccinimidyl suberate (DSS) to protein G magnetic beads to precipitate MAVS 
oligomers. Similarly, mitochondria from MAVS-WT, MAVS-KO, and MAVS-C79F MEFs 
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were isolated with Tom22 antibody-conjugated magnetic beads. (B) Quality and purity 
of MAVS oligomers precipitated from SLE patient plasma (samples P1–P4) were 
assessed using gel electrophoresis. Plasma from a healthy individual (C1) served as a 
control. (C) Mitochondria from MAVS-WT and MAVS-KO MEFs were untreated or 
treated with GOx or MitoQ, and exposed to patient-derived MAVS oligomers. 
Mitochondrial lysates were then separated during gel electrophoresis and subsequent 
immunoblots were probed for the presence of MAVS oligomers. (D) Similarly, purified 
mitochondria harboring the MAVS-C79F variant or a mix of MAVS-WT and MAVS-C79F 
were also exposed to purified MAVS from an SLE patient (P2).  
 
Figure 7. SLE-derived MAVS oligomers are internalized by DCs and induce 
mitochondrial MAVS aggregation. (A) SLE patient plasma-derived MAVS oligomers 
were labeled with Alx546 or Alx488 fluorophores. Gel electrophoresis confirmed labeling 
efficiency by direct excitation of the in-gel fluorescence of control (C1–C4) and patient 
(P1–P4) samples (upper panels). (B) Murine BMDCs or human monocyte-derive DCs 
(hDC) were cultivated with either SLE patient-derived fluorescent MAVS oligomers (P3) 
or plasma from a healthy control subject (C1). Shown are confocal microscopic images 
analyzing the localization of internalized Alx546-labeled MAVS oligomers. MitoTracker 
green (50 nM) and Hoechst 33342 (10 µg/ml) were used to define mitochondria and 
nuclei, respectively. (C) MAVS internalization kinetics was calculated by measuring 
increase in intracellular Alx546 fluorescence intensity over time as a ratio (P3/C1) 
following exposure to either SLE patient (P3) or healthy control (C1) labeled MAVS. 
Data are shown as mean ± SEM. (D) Correlation coefficients for mitochondria 
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(MitoTracker green) and Alx546-labeled MAVS oligomers were calculated to determine 
the co-localization of mitochondria and MAVS oligomers. For data collection, 200 
individual cells were examined. (E) IFN-I secretion in response to MAVS internalization 
from SLE patients (P2-P4) or healthy controls (C1, C2) using BMDC from WT or MAVS-
KO mice was measured by ELISA. (F) MAVS oligomerization in the mitochondrial 
fraction of BMDCs, which were exposed to SLE patient-derived and fluorescently 
labeled MAVS (top panel). Total mitochondrial MAVS was detected following treatment 
with reducing agent β-Me. The interaction of the patient-derived MAVS-oligomers with 
mitochondria was confirmed by the detection of the fluorophore using an anti-Alx488 
antibody or direct in-gel fluorescence (middle panel). Mitochondrial BMDC fractions 
from mice lacking MAVS served as controls (lower panels). (G) To verify that neither 
MAVS expression nor MAVS oligomerization could be induced by the fluorophore alone, 
BMDCs were treated with increasing concentrations of free Alx488 dye and the 
mitochondrial fraction was probed for the amount of MAVS at mitochondria, and Alx488 
was detected by anti-Alx488 antibody. (H) The mitochondrial fraction of BMDCs 
exposed to SLE patient (P2–P4) and control (C1) plasma-derived MAVS oligomers was 
immunoblotted to determine recruitment of signaling molecules downstream of MAVS 
activation. Shown immunoblots are representative of three experiments. Statistical 
analyses performed were two-way ANOVA (C-E), followed by Tukey’s Multiple 
Comparisons Test to examine specific comparisons. (**p < 0.005). 
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Table 1. Genotype and activity of SLE patients 
 
Patient  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  
 
C79F - - - - - - - nd nd - - nd nd - - - -  
Q93E + - - - + + - nd nd - - nd nd - - + - 
MAVS + + +++ + ++++ + +++ ++ +++ ++ +++ ++ - + - - ++ 
IFN-I + + ++++ + ++++ + +++ +++ ++++ ++++ +++ ++++ + + - ++ ++  
SLEDAI 4 6 10 0 4 0 4 7 12 9 6 8 6 4 4 0 0  
 
MAVS oligomerization and IFN-I change were normalized among all 17 patients, where the highest patient value was 
defined as 1. MAVS oligomerization and IFN-I per patient were scored with +, ++, +++, ++++, when the absolute mean 
value after normalization was falling between 0 and 0.25, 0.25 and 0.5, 0.5 and 0.75 or 0.75 and 1.00 respectively. (nd – 
not determined)
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SUPPLEMENTARY MATERIALS 
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Supplementary Figure 1. Measurement of mROS, mitochondrial mass and 
mitochondrial phenotype. (A) Generation of mROS in WT, MAVS-deficient, 
reconstituted, or minimal-MAVS (truncated at position Gln148) expressing MEF in 
response to infection with CVB3 or SINV, or transfection with 5′-ppp–RNA, was 
quantified by FACS using 50 nM MitoSox Red. (B) Flow cytometric quantification of total 
mitochondrial mass in these cells was achieved by MitoTracker DeepRed. (C) The 
basal extracellular acidification rate (ECAR), a readout of lactate production by 
glycolysis, was measured by Seahorse Flux Analyzer. (D) The ultrastructural 
morphology of mitochondria in WT and MAVS-deficient MEFs following infection was 
observed by transmission electron microscopy. (E) The dimensions of WT and MAVS-
deficient mitochondria were calculated from representative electron microscopic 
images, and the percentage of elongated mitochondria was calculated from 5 
micrographs. 
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Supplementary Figure 2. MAVS oligomers are not artificially formed during 
sample processing, homogenization or lysis, and IL-6 expression and secretion in 
the presence of ROS is independent of RIG-I helicases. (A) Freshly prepared PBMC 
were treated with GOx or infected with SINV, and subsequently homogenized in buffer 
containing 100 µM iodoacetamide. (B) Transcriptional activity and secretion of IL-6 in 
WT (1), RIG-I-KO (2), RIG-I-KO/MDA5-KD (3) and MAVS-KO (4) MEFs in response to 
GOx, MitoPQ, poly(I:C) and 5’-ppp-RNA was measured by (B) qPCR and (C) ELISA. 
One-way ANOVA was used for statistical analysis of IFN-²  and IL-6 mRNA expression 
and secretion (*p < 0.05, ***p < 0.005, ****p < 0.0005). (D) As a control, dsDNA 
treatment was used to determine by qPCR whether WT, RIG-I-KO, RIG-I-KO/MDA5-KD 
and MAVS-KO MEFs can upregulate IFN-²  and IL-6 mRNA in a RIG-I-like independent 
manner. Statistical analysis by one-way ANOVA of mRNA expression showed non-
statistical (ns) differences.  
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Supplementary Figure 3. MAVS oligomers are not artificially formed during 
processing, homogenization or lysis of SLE patient samples. 
PBMC of SLE patients (n=9) and healthy, sex-and age matched control donors (n=9) 
were isolated by Ficoll gradient centrifugation as described, and cells and 
corresponding plasma samples were supplemented with 100 µM iodoacetamide before 
analysis.  
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Supplementary Figure 4. Analysis of mitochondrial respiration in PBMC 
subpopulations. OCR in B cells (A), T cells (B) and monocytes (C) isolated from 
patients with SLE was measured following the sequential addition of oligomycin, FCCP, 
and a combination of antimycin A and rotenone. B cells, T cells and monocytes (D, E, 
and F, respectively) from healthy individuals served as controls. Shown are 
representative data of three independent experiments. 
 
 
 
 
 
